Strategies for a Biomarker-Driven Approach to Locally Advanced Esophageal Cancer

Abstract

Treatment paradigms for esophageal cancer are evolving and there is a growing need for prognostic and predictive biomarkers to guide clinical decision making. Perioperative chemotherapy has emerged as a standard of care for esophageal adenocarcinoma (EAC), yet some patients with an elevated local recurrence risk or poor tolerance to intensified chemotherapy may benefit from neoadjuvant therapy including radiation. Biomarkers for predicting treatment response to radiation, chemotherapy, and immunotherapy in other gastrointestinal malignancies and solid tumors are emerging that could be used to personalize treatment approaches. Recent trials have demonstrated the safety and efficacy of a watch-and-wait approach for both EAC and esophageal squamous cell carcinoma, but with pathologic complete response rates ranging from 10 to 49% it will be critical to improve patient selection for omission of surgery. Further prospective study is warranted to evaluate the clinical efficacy of a biomarker-driven treatment approach.

Keywords

esophageal cancer - biomarkers - radiation therapy

Publikationsverlauf

Eingereicht: 10. November 2024

Angenommen: 18. November 2024

Artikel online veröffentlicht:
18. Dezember 2024

• References

• 1 Rodriguez GM, DePuy D, Aljehani M. et al. Trends in epidemiology of esophageal cancer in the US, 1975-2018. JAMA Netw Open 2023; 6 (08) e2329497
• 2 Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349 (23) 2241-2252
• 3 Lou F, Sima CS, Adusumilli PS. et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol 2013; 8 (12) 1558-1562
• 4 Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). Journal of Clinical Oncology. Accessed September 28, 2024 at: https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA1
• 5 Reynolds JV, Preston SR, O'Neill B. et al; Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol 2023; 8 (11) 1015-1027
• 6 van der Wilk BJ, Eyck BM, Wijnhoven BPL. et al. LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial. Ann Oncol 2023; 34: S1317
• 7 Qian D, Chen X, Shang X. et al. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: a phase II random. Radiother Oncol 2022; 174: 1-7
• 8 Pape M, Vissers PAJ, Beerepoot L. et al. Treatment patterns and overall survival for recurrent esophageal or gastroesophageal junctional cancer: a nationwide European population-based study. J Clin Oncol Published online January 20, 2021
• 9 Gaber C, Abdelaziz A, Okpara E, Lee T, Klempner SJ, Nipp RD. Pathologic complete response among patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: a meta-analysis. J Clin Oncol Published online January 20, 2024
• 10 van Hagen P, Hulshof MCCM, van Lanschot JJB. et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366 (22) 2074-2084
• 11 Frontiers | Pathway-Based Analysis Revealed the Role of Keap1-Nrf2 Pathway and PI3K-Akt Pathway in Chinese Esophageal Squamous Cell Carcinoma Patients With Definitive Chemoradiotherapy. Accessed September 28, 2024 at: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.799663/full
• 12 Identification of Radioresponsive Genes in Esophageal Cancer from Longitudinal and Single Cell Exome Sequencing - ClinicalKey. Accessed September 28, 2024 at: https://www-clinicalkey-com.laneproxy.stanford.edu/#!/content/playContent/1-s2.0-S0360301620312566?scrollTo=%23hl0000329
• 13 Clements HA, Underwood TJ, Petty RD. Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma. Br J Cancer 2024; 130 (01) 9-18
• 14 A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO) | Anticancer Research. Accessed September 28, 2024 at: https://ar.iiarjournals.org/content/39/9/5123
• 15 Wang F, Xia X, Yang C. et al. SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy. Clin Cancer Res 2018; 24 (13) 3176-3185
• 16 Cerami E, Gao J, Dogrusoz U. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2 (05) 401-404
• 17 Gao J, Aksoy BA, Dogrusoz U. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6 (269) pl1
• 18 de Bruijn I, Kundra R, Mastrogiacomo B. et al; AACR Project GENIE BPC Core Team, AACR Project GENIE Consortium. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res 2023; 83 (23) 3861-3867
• 19 Gao YB, Chen ZL, Li JG. et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 2014; 46 (10) 1097-1102
• 20 Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women's Hospital, Broad Institute, Brown University, Case Western Reserve University, Dana-Farber Cancer Institute, Duke University, Greater Poland Cancer Centre, Harvard Medical School, Institute for Systems Biology, KU Leuven, Mayo Clinic, Memorial Sloan Kettering Cancer Center, National Cancer Institute, Nationwide Children's Hospital, Stanford University, University of Alabama, University of Michigan, University of North Carolina, University of Pittsburgh, University of Rochester, University of Southern California, University of Texas MD Anderson Cancer Center, University of Washington, Van Andel Research Institute, Vanderbilt University, Washington University, Genome Sequencing Center: Broad Institute, Washington University in St. Louis, Genome Characterization Centers: BC Cancer Agency, Broad Institute, Harvard Medical School, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University of North Carolina, University of Southern California Epigenome Center, University of Texas MD Anderson Cancer Center, Van Andel Research Institute, Genome Data Analysis Centers: Broad Institute, Brown University, Harvard Medical School, Institute for Systems Biology, Memorial Sloan Kettering Cancer Center, University of California Santa Cruz, University of Texas MD Anderson Cancer Center, Biospecimen Core Resource: International Genomics Consortium, Research Institute at Nationwide Children's Hospital, Tissue Source Sites: Analytic Biologic Services, Asan Medical Center, Asterand Bioscience, Barretos Cancer Hospital, BioreclamationIVT, Botkin Municipal Clinic, Chonnam National University Medical School, Christiana Care Health System, Cureline, Duke University, Emory University, Erasmus University, Indiana University School of Medicine, Institute of Oncology of Moldova, International Genomics Consortium, Invidumed, Israelitisches Krankenhaus Hamburg, Keimyung University School of Medicine, Memorial Sloan Kettering Cancer Center, National Cancer Center Goyang, Ontario Tumour Bank, Peter MacCallum Cancer Centre, Pusan National University Medical School, Ribeirão Preto Medical School, St. Joseph's Hospital &Medical Center, St. Petersburg Academic University, Tayside Tissue Bank, University of Dundee, University of Kansas Medical Center, University of Michigan, University of North Carolina at Chapel Hill, University of Pittsburgh School of Medicine, University of Texas MD Anderson Cancer Center, Disease Working Group: Duke University, Memorial Sloan Kettering Cancer Center, National Cancer Institute, University of Texas MD Anderson Cancer Center, Yonsei University College of Medicine, Data Coordination Center: CSRA Inc., Project Team: National Institutes of Health. Integrated genomic characterization of oesophageal carcinoma. Nature 2017; 541 (7636): 169-175
• 21 Dulak AM, Stojanov P, Peng S. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013; 45 (05) 478-486
• 22 Spirina LV, Avgustinovich AV, Bakina OV. et al. Targeted sequencing in gastric cancer: association with tumor molecular characteristics and FLOT therapy effectiveness. Curr Issues Mol Biol 2024; 46 (02) 1281-1290
• 23 Marcisz-Grzanka K, Kotowicz B, Nowak A. et al. Interleukin-6 as a predictive factor of pathological response to FLOT regimen systemic treatment in locally advanced gastroesophageal junction or gastric cancer patients. Cancers (Basel) 2024; 16 (04) 757
• 24 Schulz C, Zhang W, Lenz HJ. et al. Germline polymorphisms (SNPs) to predict toxicity and efficacy in FLOT-treated patients with locally advanced gastroesophageal junction or gastric adenocarcinoma—data from the NeoFLOT study. Transl Cancer Res 2018; 7 (06)
• 25 Leong T, Smithers BM, Michael M. et al. Preoperative Chemoradiotherapy for Resectable Gastric Cancer. New England Journal of Medicine. Published online September 14, 2024. Accessed October 8, 2024 at: https://www.nejm.org/doi/full/10.1056/NEJMoa2405195
• 26 Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas | Clinical Cancer Research | American Association for Cancer Research. Accessed October 8, 2024 at: https://aacrjournals.org/clincancerres/article/27/23/6343/675038/Results-and-Molecular-Correlates-from-a-Pilot
• 27 Lorenzen S, Biederstädt A, Ronellenfitsch U. et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 2020; 20 (01) 886
• 28 Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer | New England Journal of Medicine. Accessed October 8, 2024 at: https://www.nejm.org/doi/full/10.1056/NEJMoa2032125
• 29 Janjigian YY, Al-Batran SE, Wainberg ZA. et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. JCO 2024; 42 (3, Suppl): LBA246-LBA246
• 30 Jang JY, Jeong SY, Kim ST. Tumor mutational burden as a potential predictive marker for the efficacy of immunotherapy in advanced gastric cancer. JCO 2023; 41 (4, Suppl): 324-324
• 31 High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers | Molecular Cancer Therapeutics | American Association for Cancer Research. Accessed October 8, 2024 at: https://aacrjournals.org/mct/article/19/10/2139/92687/High-Tumor-Mutational-Burden-Correlates-with
• 32 Lentz RW, Friedrich T, Hu J. et al. Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers. JCO 2021; 39 (15, Suppl): e14559-e14559
• 33 Tie J, Wang Y, Tomasetti C. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016; 8 (346) 346ra92
• 34 Abbosh C, Frankell AM, Harrison T. et al; TRACERx Consortium. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 2023; 616 (7957): 553-562
• 35 Nakamura Y, Watanabe J, Akazawa N. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med 2024; 30 (11) 3272-3283
• 36 Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol 2021; 18 (05) 297-312
• 37 Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): A prospective multicenter diagnostic cohort study in Asia. | Journal of Clinical Oncology. Accessed September 28, 2024 at: https://ascopubs.org/doi/10.1200/JCO.2024.42.23_suppl.196
• 38 Egyud M, Tejani M, Pennathur A. et al. Detection of circulating tumor DNA in plasma: a potential biomarker for esophageal adenocarcinoma. Ann Thorac Surg 2019; 108 (02) 343-349
• 39 Fujisawa R, Iwaya T, Endo F. et al. Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer. Carcinogenesis 2021; 42 (10) 1239-1249
• 40 Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers | JCO Precision Oncology. Accessed September 28, 2024 at: https://ascopubs.org/doi/abs/10.1200/PO.22.00420
• 41 Klevebro F, Alexandersson von Döbeln G, Wang N. et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016; 27 (04) 660-667
• 42 Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial - The Lancet. Accessed October 19, 2024 at: https://www-thelancet-com.laneproxy.stanford.edu/journals/lancet/article/PIIS0140-6736(18)32557-1/fulltext